Clinical Articles

Your body's repair cells send out tiny "healing packages" that can help fix a heart after a heart attack. New medical studies show that using special patches to keep these packages in place helps the heart heal much faster.

Using your own blood during surgery can help keep your mind clear and sharp while you recover. This study shows that using your own cells instead of a donor's reduces the risk of confusion and helps you heal faster.

A 2025 prospective observational study tested whether a single administration of **adipose-derived mesenchymal stem cells (ADSCs)** produces immediate changes in blood markers and muscle strength in people with neurodegenerative and respiratory conditions. The study measured serum cholinesterase ...

New findings show that certain circular RNAs can help control how your body's repair cells turn into different types of cells, which is important for healing and growth. This could lead to better treatments for conditions like osteoporosis and muscle loss. Understanding these processes may improve future healing therapies.

Newly modified plant compounds called pentacyclic triterpenes could offer better treatments for diseases like cancer and diabetes by improving how well they work in the body. These changes make them easier for our bodies to use, potentially leading to more effective healing options in the future.

New findings reveal that the germ cell nuclear factor (GCNF) plays a crucial role in neural stem cell development by suppressing Oct4, a key gene for maintaining pluripotency. This regulation is vital for the transition of primitive neural stem cells to definitive ones, potentially unlocking new avenues for regenerative therapies in neurodegenerative diseases.

New findings reveal that the p53 protein is essential for guiding stem cells to differentiate safely, potentially reducing cancer risks. By reactivating p53, researchers could enhance stem cell therapies and develop innovative cancer treatments, paving the way for safer regenerative medicine.

New research highlights the critical role of insulin-like growth factor 1 receptor (IGF1R) in enhancing stem cell self-renewal and therapeutic potential. Understanding IGF1R signaling could significantly improve regenerative treatments, making stem cell preservation more valuable for future health needs.

Hair follicles contain several kinds of stem cells. One group, called hair follicle-associated‑pluripotent (HAP) stem cells, sits in the bulge region of the follicle and expresses the protein nestin. Laboratory studies show HAP cells can turn into many different cell types — neurons, glial cells (support cells in nerves), skin cells, smooth muscle, heart muscle, pigment cells and more [2,10,19,25]. HAP cells are easy to collect from the scalp, do not require genetic reprogramming, do not form tu

Authors: Isabel Dorn, Katharina Klich, Marcos J Arauzo-Bravo, Martina Radstaak, Simeon Santourlidis, Foued Ghanjati, Teja F Radke, Olympia E Psathaki, Gunnar Hargus, Jan Kramer, Martin Einhaus, Jeong Beom Kim, Gesine Kogler, Peter Wernet, Hans R Scholer, Peter Schlenke, Holm Zaehres

Loss or severe damage of the corneal epithelium (the clear, outer surface of the eye) can cause vision loss. Donor tissue for direct corneal or limbal epithelial transplantation is limited, and allogeneic grafts carry a rejection risk. Researchers are developing ways to turn a patient’s own stem cells into corneal epithelial cells for transplantation. This review summarizes what works so far with human stem cells — especially mesenchymal stem/stromal cells (MSCs) and pluripotent stem cells (ESCs

Authors: Stefano Manodoro, Matteo Frigerio, Marta Barba, Sara Bosio, Luigi Antonio de Vitis, Anna Maria Marconi

Authors: M. Mashayekhi et al. (published Jan 6, 2021)

Jesmine Banu; Nishat Jahan; Shaheen A. Anwary; Mostafa Tarique; Itrat Aziz; Nastaran Laskar; M. Rifat Hasan; Chowdhury F. Alamgir; Maliha Darmini

Neeta Singh, Bhawani Shekhar, Sujata Mohanty, Sunesh Kumar, Tulika Seth, Bhavana Girish

Authors: Michael Mitterberger et al.

Authors: Yizhen Sima & Yisong Chen (original review published Cell & Bioscience, 2020)

Pelvic floor disorders (PFDs) — such as stress urinary incontinence (SUI), anal (fecal) incontinence, and pelvic organ prolapse — result from weakness or injury to muscles, nerves, or connective tissues of the pelvic floor. Traditional treatments (rehabilitation, surgery) often give incomplete relief. Stem cell (SC) therapy is being tested as a regenerative alternative.

Authors: Mahta Hadidi, Keyvan Karimabadi, Elham Ghanbari, Leila Rezakhani*, Mozafar Khazaei*

BioCardia announced that the University of Wisconsin School of Medicine and Public Health enrolled its first patient in the Phase 3 CardiAMP HF II trial. This trial is testing CardiAMP, an autologous (patient’s own) bone marrow cell therapy, in people with ischemic heart failure with reduced ejection fraction (HFrEF) who still have signs of heart stress despite optimized medical care.

The authors show that bone marrow–derived mesenchymal stem cells (BM-MSC) can reverse stroke-induced thymic atrophy, restore thymic structure, and normalize peripheral T-cell populations in a mouse tMCAO model.

AIMS: Regenerative treatment with mesenchymal stromal cells (MSCs) has been promising in patients with ischaemic heart failure but needs confirmation in larger randomized trials. We aimed to study effects of intra-myocardial autologous bone marrow-derived MSC treatment in patients with severe ischaemic heart failure. __METHODS AND RESULTS__ The MSC-HF trial is a randomized, double-blind, placebo-controlled trial. Patients were randomized 2 : 1 to intra-myocardial injections of MSC or placebo, respectively. The primary endpoint was change in left ventricular end-systolic volume (LVESV), measured by magnetic resonance imaging or computed tomography at 6 months follow-up. Sixty patients aged 30-80 years with severe ischaemic heart failure, New York Heart Association (NYHA) classes II-III, left ventricular ejection fraction (LVEF) <45% and no further treatment options were randomized. Fifty-five patients completed the 6-month follow-up (37 MSCs vs. 18 placebo). At 6 months, LVESV was reduced in the MSC group: -7.6 (95% CI -11.8 to -3.4) mL (P = 0.001), and increased in the placebo group: 5.4 (95% CI -0.4 to 11.2) mL (P = 0.07). The difference between groups was 13.0 (95% CI 5.9-20.1) mL (P = 0.001). Compared with placebo, there were also significant improvements in LVEF of 6.2% (P<0.0001), stroke volume of 18.4 mL (P < 0.0001), and myocardial mass of 5.7 g (P = 0.001). No differences were found in NYHA class, 6-min walking test and Kansas City cardiomyopathy questionnaire. No side effects were identified. __CONCLUSION__ Intra-myocardial injections of autologous culture expanded MSCs were safe and improved myocardial function in patients with severe ischaemic heart failure.

A meta-analysis of 18 clinical trials (565 patients) demonstrates that mesenchymal stem cell (MSC) therapy significantly improves pain (VAS) and knee function (IKDC, Lysholm, WOMAC) in osteoarthritis patients, with sustained efficacy up to 24 months and peak benefits at 12-24 months post-treatment. Outcomes were enhanced by arthroscopic debridement, activation agents, and lower Kellgren-Lawrence grades, but showed no dose-response to MSC numbers. MSC treatment offers promising pain relief and functional gains for knee osteoarthritis.

While mesenchymal stem cells represent an interesting cell source for regenerative medicine, several points have to be investigated to improve their use in clinical, and in particular in the elderly population. This work studied the proliferation capacity of mesenchymal stem cells isolated from human bone marrow in function of donor's age. Doubling time after in vitro culture, clonogenicity and phenotype were analyzed in 17 samples ranging from 3 to 85 years old (mean 47 ± 27). Results showed an increase in the doubling time for cell coming from old donor compared to cells coming from young ones. This was accompanied by a decrease in clonogenicity while no changes were observe in cell phenotype. In conclusion, this study showed an effect of donor's age on the proliferation capacity of mesenchymal stem cells isolated from bone marrow that was correlated to a decrease in clonogenicity. The comprehension of molecular mechanism involved in this process could help to improve the clinical application of mesenchymal stem cells.

Aging is a complex process of damage accumulation, and has been viewed as experimentally and medically intractable. The number of patients with age-associated diseases such as type 2 diabetes mellitus (T2DM), osteoporosis, Alzheimer's disease (AD), Parkinson's disease, atherosclerosis, and cancer has increased recently. Aging-related diseases are related to a deficiency of the immune system, which results from an aged thymus and bone marrow cells. Intra bone marrow-bone marrow transplantation (IBM-BMT) is a useful method to treat intractable diseases. This review summarizes findings that IBM-BMT can improve and treat aging-related diseases, including T2DM, osteoporosis and AD, in animal models.

__Increasing evidence suggests that the loss of functional stem cells may be important in the aging process.__ Our experiments were originally aimed at testing the idea that, in the specific case of age-related osteoporosis, declining function of osteogenic precursor cells might be at least partially responsible. To test this, aging female mice were transplanted with mesenchymal stem cells from aged or young male donors. We find that transplantation of young mesenchymal stem cells significantly slows the loss of bone density and, surprisingly, prolongs the life span of old mice. These observations lend further support to the idea that age-related diminution of stem cell number or function may play a critical role in age-related loss of bone density in aging animals and may be one determinant of overall longevity.

This study confirms that long-term cryopreservation of bone marrow for up to 7.8 years does not negatively impact hematopoietic stem cell viability or engraftment success. Results indicate that early-stage marrow collection can effectively preserve stem cell quality before cumulative damage from chemotherapy or radiation occurs. This research supports the long-term storage of autologous bone marrow as a reliable option for future transplantation.

Tissue renewal is a well-known phenomenon by which old and dying-off cells of various tissues of the body are replaced by progeny of local or circulating stem cells (SCs). An interesting question is whether donor SCs are capable to prolong the lifespan of an aging organism by tissue renewal. In this work, we investigated the possible use of bone marrow (BM) SC for lifespan extension. To this purpose, chimeric C57BL/6 mice were created by transplanting BM from young 1.5-month-old donors to 21.5-month-old recipients. Transplantation was carried out by means of a recently developed method which allowed to transplant without myeloablation up to 1.5 × 10(8) cells, that is, about 25% of the total BM cells of the mouse. As a result, the mean survival time, counting from the age of 21.5 months, the start of the experiment, was +3.6 and +5.0 (±0.1) months for the control and experimental groups, respectively, corresponding to a 39 ± 4% increase in the experimental group over the control. In earlier studies on BM transplantation, a considerably smaller quantity of donor cells (5 × 10(6)) was used, about 1% of the total own BM cells. The recipients before transplantation were exposed to a lethal (for control animals) X-ray dose which eliminated the possibility of studying the lifespan extension by this method.

As human lifespan increases, a greater fraction of the population is suffering from age-related cognitive impairments, making it important to elucidate a means to combat the effects of aging. Here we report that exposure of an aged animal to young blood can counteract and reverse pre-existing effects of brain aging at the molecular, structural, functional and cognitive level. Genome-wide microarray analysis of heterochronic parabionts--in which circulatory systems of young and aged animals are connected--identified synaptic plasticity-related transcriptional changes in the hippocampus of aged mice. Dendritic spine density of mature neurons increased and synaptic plasticity improved in the hippocampus of aged heterochronic parabionts. At the cognitive level, systemic administration of young blood plasma into aged mice improved age-related cognitive impairments in both contextual fear conditioning and spatial learning and memory. Structural and cognitive enhancements elicited by exposure to young blood are mediated, in part, by activation of the cyclic AMP response element binding protein (Creb) in the aged hippocampus. Our data indicate that exposure of aged mice to young blood late in life is capable of rejuvenating synaptic plasticity and improving cognitive function.

Bone marrow-derived stem cells may modulate renal injury, but the effects may depend on the age of the stem cells. Here we investigated whether bone marrow from young mice attenuates renal aging in old mice. We radiated female 12-mo-old 129SvJ mice and reconstituted them with bone marrow cells (BMC) from either 8-wk-old (young-to-old) or 12-mo-old (old-to-old) male mice. Transfer of young BMC resulted in markedly decreased deposition of collagen IV in the mesangium and less β-galactosidase staining, an indicator of cell senescence. These changes paralleled reduced expression of plasminogen activator inhibitor-1 (PAI-1), PDGF-B (PDGF-B), the transdifferentiation marker fibroblast-specific protein-1 (FSP-1), and senescence-associated p16 and p21. __Tubulointerstitial and Glomerular Cells__ Tubulointerstitial and glomerular cells derived from the transplanted BMC did not show β-galactosidase activity, but after 6 mo, there were more FSP-1-expressing bone marrow-derived cells in old-to-old mice compared with young-to-old mice. Young-to-old mice also exhibited higher expression of the anti-aging gene Klotho and less phosphorylation of IGF-1 receptor β. Taken together, these data suggest that young bone marrow-derived cells can alleviate renal aging in old mice. Direct parenchymal reconstitution by stem cells, paracrine effects from adjacent cells, and circulating anti-aging molecules may mediate the aging of the kidney.

Human bone marrow-derived mesenchymal cells contain mesenchymal stem cells (MSCs), which are well known for their osteo/chondrogenic potential and can be used for bone reconstruction. This article reports the viability of cryopreserved human mesenchymal cells and a comparison of the osteogenic potential between noncryopreserved and cryopreserved human mesenchymal cells with MSC-like characteristics, derived from the bone marrow of 28 subjects. The viability of cryopreserved mesenchymal cells was approximately 90% regardless of the storage term (0.3 to 37 months). It is clear by fluorescence-activated cell sorter analysis that the cell surface antigens of both noncryopreserved and cryopreserved mesenchymal cells were negative for hematopoietic cell markers such as CD14, CD34, CD45, and HLA-DR but positive for mesenchymal characteristics such as CD29 and CD105. To monitor the osteogenic potential of the cells, such as alkaline phosphatase (ALP) activity and in vitro mineralization, a subculture was conducted in the presence of dexamethasone, ascorbic acid, and glycerophosphate. No difference in osteogenic potential was found between cells with or without cryopreservation treatment. In addition, cells undergoing long-term cryopreservation (about 3 years) maintained high osteogenic potential. In conclusion, cryopreserved as well as noncryopreserved human mesenchymal cells could be applied for bone regeneration in orthopedics.

Overview of MSC therapy for multiple clinical trials, showing broad potential for the clinical use of hMSCs with no reported serious adverse events.

This was a prospective, randomized, double-blind, placebo-controlled trial - which is considered the gold standard for clinical research. Patients used their own stem cells to regenerate damaged heart muscle whose heart failure was caused by blocked coronary arteries (ischemic), showing fewer heart-related complications and better symptoms compared to placebo.

Researchers treated 17 heart attack patients with an infusion of stem cells taken from their own hearts. A year after the procedure, the amount of scar tissue had shrunk by about 50%.

Critical Review of multiple clinical trials using MSCs for heart disease conditions

Over 60% of patients receiving treatment for head and neck cancers experience radiation-induced salivary gland damage. The study suggests this could provide a definitive treatment rather than just symptom management for the millions of people suffering from dry mouth conditions.

Intramyocardial delivery of stem cells is more complicated than intracoronary administration, but it is safe and may provide better therapeutic outcomes.

Cell-based therapies including pluripotent and multipotent adult stem cells show proven repair and regeneration potential and are being considered as a remedy for diabetic complications, which are the most prominent reason for high mortality among diabetic patients. They may also provide a long-term cure for diabetes and its complications.

No alternative intervention strategies match, or even get close to, the clinical outcome achieved in a considerable number of patients treated with autologous stem cell transplantation. We propose that this patient group should be identified, diligently informed and offered the possible benefits of an extended period of insulin-free and burden-free survival,

Reports summarized here suggest significant potential for the use of mesenchymal stem cells in osteoarthritis.

MSCs offer a promising emerging therapy for patients with IBD due to their immunosuppressive properties, ability to migrate to areas of injury, and demonstration of colonic healing.

Stem cell-based approaches can induce poststroke recovery via mechanisms, such as neuronal replacement, promotion of angiogenesis, induction of brain plasticity, reduction of cell death, or immunomodulation.

This study provides strong evidence that autologous hematopoietic stem cell transplantation offers superior long-term clinical outcomes compared to two of the most effective current disease-modifying therapies for relapsing multiple sclerosis, particularly in terms of preventing relapses and maintaining sustained clinical benefit over a 5-year follow-up period.

Changes in neurological deficits and improvements in function were compared between two groups for 1 year after symptom onset. Patients treated with autologous MSCs showed significant improvement in both cognition and mobility.

MSC therapy is safe and effective in treating IS by improving the neurological deficits, motor function and daily life quality of patients.

Numerous studies reported better results when the mesenchymal stem cells were used in co-culture with other cells or used in scaffolds. Mesenchymal stem cells were also found to have an immune-modulatory role, which can improve surgical outcome.

All of the children demonstrated neurological improvement, with significant reductions in the number of both epileptic seizures and SE episodes, with an improved quality of life.

This study supports the benefit of intrathecal administration of autologous MSCs for the treatment of neuropathic pain in patients with spinal cord injuries.

Patients receiving MSCs saw significant improvement in standing and walking time, with reduced need for medication.

Injection of imesenchymal stem cells directly into damaged spinal discs reduce back pain and help heal the disc tissue, potentially avoiding the need for surgery. This treatment works best when used early in disc problems and could help keep the spine working normally, preventing further damage and the need for more invasive procedures later.

In certain autoimmune diseases AHSCT can be good choice when conventional therapy failed.

Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy with promising results.

This study illustrate that quality‐of‐life and functional capacity parameters improve with cell‐based therapy even if classic measures of cardiac function, such as ejection fraction, do not.

Current evidence points toward stem cell therapy as an effective treatment for human patients with DFU

Intravenous transplantation of bone marrow-derived mononuclear cells (BMMCs) successfully improved cognitive function and prevented neurodegeneration in two different Alzheimer's disease mouse models.

As we age, stem cells lose efficacy and ability to heal.

This phase II randomized trial demonstrates that autologous hematopoietic stem cell transplantation (AHSCT) is significantly more effective than mitoxantrone at reducing MRI-detected disease activity in patients with aggressive multiple sclerosis. Results showed a 79% reduction in new T2 lesions and a significant decrease in relapse rates, supporting the need for larger phase III clinical trials.